Fixed drug eruption due To 2,3-dimercapto-1-propanesulfonic acid (DMPS) treatment for mercury poisoning: a rare adverse effect

被引:3
作者
Erden, Fatma [1 ]
Agis, Erol Rauf [2 ]
Gunduzoz, Meside [3 ]
Yilmaz, Omer Hinc [4 ]
机构
[1] Ankara Occupat Dis Hosp, Dept Dermatol & Venereol, Ankara, Turkey
[2] Ankara Occupat Dis Hosp, Clin Pharmacol, Ankara, Turkey
[3] Ankara Occupat Dis Hosp, Clin Family Med, Ankara, Turkey
[4] Yildirim Beyazit Univ, Fac Med, Dept Publ Hlth, Ankara, Turkey
关键词
Mercury exposure intoxication; heavy metal; fixed drug eruption; 2; 3-dimercapto-1-propanesulfonic acid (DMPS); TRIMETHOPRIM-SULFAMETHOXAZOLE;
D O I
10.1080/17843286.2018.1484983
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fixed drug eruptions (FDE) are characterized by recurrent, usually solitary erythematous or dark red macular, plaque or bullous lesions, all at the same site. Among the first choices for antidotal treatment in mercury exposure, 2,3-dimercapto-1-propanesulfonic acid (DMPS) is generally a drug with a low incidence of side effects. FDE due to DMPS was not detected in our literature research and so we aimed to present this rare case. Case Report: Forty-eight-year-old male patient, gunpowder and explosives factory worker, was admitted to our hospital because of mercury exposure and we started DMPS treatment. On the second day of chelation treatment, swelling and felting on lips and complaints of wound formation in genital areas started. Annular, purple color plaque on penis with no angioedema was observed. Case was regarded as FDE. Systemic and topical steroid therapy was started after termination of chelation therapy and lesions regressed with steroids. Discussion: Drug eruptions are substantially common dermatological problems and can be seen in about 2.2% of inpatients. The most common unexpected effects of DMPS are allergic skin reactions. The clinical state regress rapidly after the cessation of chelation therapy.
引用
收藏
页码:200 / 202
页数:3
相关论文
共 12 条
  • [1] DMSA AND DMPS - WATER-SOLUBLE ANTIDOTES FOR HEAVY-METAL POISONING
    APOSHIAN, HV
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1983, 23 : 193 - 215
  • [2] Barbaud A, 1998, BRIT J DERMATOL, V139, P49
  • [3] Breathnach S.M., 2010, Rook's Textbook of Dermatology, V8th ed, P28, DOI [10.1002/9781444317633.ch75, DOI 10.1002/9781444317633.CH75]
  • [4] Elemental mercury exposure: An evidence-based consensus guideline for out-of-hospital management
    Caravati, E. Martin
    Erdman, Andrew R.
    Christianson, Gwenn
    Nelson, Lewis S.
    Woolf, Alan D.
    Booze, Lisa L.
    Cobaugh, Daniel J.
    Chyka, Peter A.
    Scharman, Elizabeth J.
    Manoguerra, Anthony S.
    Troutman, William G.
    [J]. CLINICAL TOXICOLOGY, 2008, 46 (01) : 1 - 21
  • [5] EFFICACY AND SAFETY OF RECHALLENGE WITH LOW-DOSE TRIMETHOPRIM SULFAMETHOXAZOLE IN PREVIOUSLY HYPERSENSITIVE HIV-INFECTED PATIENTS
    CARR, A
    PENNY, R
    COOPER, DA
    [J]. AIDS, 1993, 7 (01) : 65 - 71
  • [6] Djien V, 1999, ANN DERMATOL VENER, V126, P247
  • [7] Dapsone-associated fixed drug eruption
    Garcia, Daniel
    Cohen, Philip R.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (07) : 717 - 725
  • [8] An update of fixed drug eruptions in Singapore
    Heng, Y. K.
    Yew, Y. W.
    Lim, D. S. Y.
    Lim, Y. L.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (08) : 1539 - 1544
  • [9] Holtzer CD, 1998, PHARMACOTHERAPY, V18, P831
  • [10] Drugs causing fixed eruptions: a study of 450 cases
    Mahboob, A
    Haroon, TS
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 1998, 37 (11) : 833 - 838